Clinical trial
V930 First in Man (FIM) Study (V930-002)(COMPLETED)
NCT00250419 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00250419 |
|---|---|
| Title | V930 First in Man (FIM) Study (V930-002)(COMPLETED) |
| Official title | A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V-930 in Patients With Cancers Expressing HER-2 and/or CEA |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancers Expressing HER-2 and/or CEA |
| Intervention type | Biological |
| Interventions | V930 |
| Enrollment | 26 |
| Start date | Sep 1, 2005 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Nov 8, 2005 |
| Last update posted | Feb 10, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: